Rifampicin Improves Neuronal Apoptosis in LPS-stimulated Co-Cultured BV2 Cells Through Inhibition of the TLR-4 Pathway

Wei Bi,Lihong Zhu,Xiuna Jing,Zhifen Zeng,Yanran Liang,Anding Xu,Jun Liu,Songhua Xiao,Lianhong Yang,Qiaoyun Shi,Li Guo,Enxiang Tao
DOI: https://doi.org/10.3892/mmr.2014.2480
IF: 3.423
2014-01-01
Molecular Medicine Reports
Abstract:Agents inhibiting microglial activation are attracting attention as candidate drugs for neuroprotection in neurodegenerative diseases. Recently, researchers have focused on the immunosuppression induced by rifampicin. Our previous study showed that rifampicin inhibits the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators and improves neuron survival in inflammation; however, the mechanism through which rifampicin inhibits microglial inflammation and its neuroprotective effects are not completely understood. In this study, we examined the effects of rifampicin on morphological changes induced by LPS in murine microglial BV2 cells. Then we investigated, in BV2 microglia, the effects of rifampicin on two signaling pathway componentss stimulated by LPS, the Toll-like receptor-4 (TLR-4) and the nuclear factor-kappa B (NF-kappa B). In addition, we co-cultured BV2 microglia and neurons to observe the indirect neuroprotective effects of rifampicin. Rifampicin inhibited LPS-stimulated expression of the TLR-4 gene. When neurons were co-cultured with LPS-stimulated BV2 microglia, pre-treatment with rifampicin increased neuronal viability and reduced the number of apoptotic cells. Taken together, these findings suggest that rifampicin, with its anti-inflammatory properties, may be a promising agent for the treatment of neurodegenerative diseases.
What problem does this paper attempt to address?